3D in vivo dosimetry of HDR gynecological brachytherapy using micro silica bead TLDs. Issue 9 (10th August 2022)

• Record Type: Journal Article
• Authors: Jaberi, Ramin; Babaloui, Somayyeh; Siavashpour, Zahra; Moshtaghi, Maryam; Shirazi, Alireza; Joya, Musa; Gholami, Mohammad Hadi; Jafari, Shakardokht
• Is Part Of: Journal of applied clinical medical physics. Volume 23:Issue 9(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-08-10
• Subjects: 3D in vivo dosimetry -- GYN -- HDR brachytherapy -- micro silica bead TLD; Medical physics -- Periodicals; Clinical medicine -- Periodicals; Health Physics; Clinical Medicine; Electronic journals; Periodicals; Periodicals; Fulltext; Internet Resources; 610.153
• DOI: 10.1002/acm2.13729
• Languages: English
• ISSNs: 1526-9914

Abstract

Abstract: Purpose: This study aimed to evaluate the feasibility of defining an in vivo dosimetry (IVD) protocol as a patient‐specific quality assurance (PSQA) using the bead thermoluminescent dosimeters (TLDs) for point and 3D IVD during brachytherapy (BT) of gynecological (GYN) cancer using 60 Co high‐dose‐rate (HDR) source. Methods: The 3D in vivo absorbed dose verification within the rectum and bladder as organs‐at‐risk was performed by bead TLDs for 30 GYN cancer patients. For rectal wall dosimetry, 80 TLDs were placed in axial arrangements around a rectal tube covered with a layer of gel. Ten beads were placed inside the Foley catheter to get the bladder‐absorbed dose. Beads TLDs were localized and defined as control points in the treatment planning system (TPS) using CT images of the patients. Patients were planned and treated using the routine BT protocol. The experimentally obtained absorbed dose map of the rectal wall and the point dose of the bladder were compared to the TPSs predicted absorbed dose at these control points. Results: Relative difference between TPS and TLDs results were −8.3% ± 19.5% and −7.2% ± 14.6% (1SD) for rectum‐ and bladder‐absorbed dose, respectively. Gamma analysis was used to compare the calculated with the measured absorbed dose maps. Mean gamma passing rates of 84.1%, 90.8%, and 92.5% using the criteria of 3%/2 mm, 3%/3 mm, and 4%/2 mm were obtained, respectively. Eventually, a "considering level" of at least 85% as pass rate with 4%/2‐mm criteria was recommended. Conclusions: A 3D IVD protocol employing bead TLDs was presented to measure absorbed doses delivered to the rectum and bladder during GYN HDR‐BT as a reliable PSQA method. 3D rectal absorbed dose measurements were performed. Differences between experimentally measured and planned absorbed dose maps were presented in the form of a gamma index, which may be used as a warning for corrective action.